Cardiol Therapeutics (TSX: CRDL; OTCMKTS: CRTPF) announced this morning that it has qualified to trade on the OTCQX Best Market, opening up the company to stateside investors. It will commence trading today under the ticker “CRTPF”.
“Trading on the OTCQX Best Market will assist us with increasing our U.S. shareholder base and investor awareness as we prepare to launch our ultra-pure pharmaceutical CBD products in the billion dollar markets in Canada, Latin America, and Europe and initiate ground-breaking international clinical trials in heart disease later this year.”
David Elsley, President and CEO of Cardiol Therapeutics
Cardiol Therapeutics is heavily focused on the pharmaceutical application of CBD products, and is currently in the process of bringing to market several CBD based pharmaceutical products. The company currently intends to bring to market a pharmaceutical CBD later this fall in Canada.
Known as CardiolRx, the product will address a significant percentage of the total medical CBD market within Canada. Two concentrations are anticipated to be available in the second half of 2019, in the sizes of 50 mg/ml and 100 mg/ml. The main draw of which, is the lack of THC that will be present in the product – enabling the pharmaceutical to be available for children, government employees, and public servants that are currently banned from the use of THC products.
In addition to CardiolRx, Cardiol is currently working towards clinical trials for two major diseases – heart failure, and Glioblastoma Multiforme (brain tumors). Clinical trials are expected to be initiated later this year for the former, while the latter is expected to begin in the first half of 2020.
The Deep Dive has completed a full company overview on Cardiol Therapeutics, which can be found here for further information on the company.
FULL DISCLOSURE: Cardiol Therapeutics is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Cardiol Therapeutics on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.
